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Background and aims: Vascular smooth muscle cells (VSMC) migrate and proliferate to form a stabilizing
ﬁbrous cap that encapsulates atherosclerotic plaques. CD98 is a transmembrane protein made of two
subunits, CD98 heavy chain (CD98hc) and one of six light chains, and is known to be involved in cell
proliferation and survival. Because the inﬂuence of CD98hc on atherosclerosis development is unknown,
our aim was to determine if CD98hc expressed on VSMC plays a role in shaping the morphology of
atherosclerotic plaques by regulating VSMC function.
Methods: In addition to determining the role of CD98hc in VSMC proliferation and apoptosis, we utilized
mice with SMC-speciﬁc deletion of CD98hc (CD98hcﬂ/ﬂSM22aCreþ) to determine the effects of CD98hc
deﬁciency on VSMC function in atherosclerotic plaque.
Results: After culturing for 5 days in vitro, CD98hc/ VSMC displayed dramatically reduced cell counts,
reduced proliferation, as well as reduced migration compared to control VSMC. Analysis of aortic VSCM
after 8 weeks of HFD showed a reduction in CD98hc/ VSMC proliferation as well as increased apoptosis
compared to controls. A long-term atherosclerosis study using SMC-CD98hc//ldlr/ mice was per-
formed. Although total plaque area was unchanged, CD98hc/ mice showed reduced presence of VSMC
within the plaque (2.1 ± 0.4% vs. 4.3 ± 0.4% SM22a-positive area per plaque area, p < 0.05), decreased
collagen content, as well as increased necrotic core area (25.8 ± 1.9% vs. 10.9 ± 1.6%, p < 0.05) compared
to control ldlr/ mice.
Conclusions: We conclude that CD98hc is required for VSMC proliferation, and that its deﬁciency leads to
signiﬁcantly reduced presence of VSMC in the neointima. Thus, CD98hc expression in VSMC contributes
to the formation of plaques that are morphologically more stable, and thereby protects against
atherothrombosis.
© 2016 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
During progression of atherosclerosis, transformation of
vascular smooth muscle cells (VSMC) from the quiescent contrac-
tile phenotype towards the proliferative migratory phenotype into
the plaque area to form a ﬁbrous cap is believed to be an essential
step in the formation of stable plaques [1]. The two major pheno-
types of VSMC include fully differentiated, contractile cells
responsible for vasodilation and vasoconstriction, and migratory,
proliferative cells that are activated during growth or injury [2].
During atherosclerosis development, VSMC respond to mediators
such as platelet derived growth factor (PDGF)eBB, endothelin-1,
thrombin, IFN-g and IL-1 secreted by endothelial cells [3] and
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